Kymera Therapeutics Inc Total Liabilities
Kymera Therapeutics Inc total liabilities. Based on the latest financial reports, Kymera Therapeutics Inc (KYMR) has total liabilities worth $139.85 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check KYMR cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Kymera Therapeutics Inc (2018–2025)
Total liabilities of Kymera Therapeutics Inc from 2018 to 2025. This chart illustrates how Kymera Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. Explore Kymera Therapeutics Inc (KYMR) long-term investment share to see how much of total assets are deployed in long-term investments.
Kymera Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Kymera Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Crinetics Pharmaceuticals Inc
NASDAQ:CRNX
|
USA | $129.92 Million |
|
Li Auto Inc
NASDAQ:LI
|
USA | $74.74 Billion |
|
Shanghai International Airport Co Ltd
SHG:600009
|
China | CN¥26.78 Billion |
|
Baloise Holding AG
SW:BALN
|
Switzerland | CHF75.34 Billion |
|
Embraer S.A
F:EMY
|
Germany | €9.11 Billion |
|
Sibanye Gold Ltd ADR
NYSE:SBSW
|
USA | $105.47 Billion |
|
CATHAY PAC.AIRW.HD-20ADR5
F:CTYA
|
Germany | €116.93 Billion |
|
Sasol Ltd
JSE:SOL
|
South Africa | ZAC193.78 Billion |
Liability Composition Analysis (2018–2025)
This chart breaks down Kymera Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see how large is Kymera Therapeutics Inc's balance sheet.
Liquidity & Leverage Metrics
Kymera Therapeutics Inc Total Liabilities Ratios Explained
Kymera Therapeutics Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 9.83 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.09 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.08 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Kymera Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Kymera Therapeutics Inc (2018–2025)
The table below shows the annual total liabilities of Kymera Therapeutics Inc from 2018 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $163.15 Million | +14.56% |
| 2024-12-31 | $142.42 Million | -21.22% |
| 2023-12-31 | $180.79 Million | +60.01% |
| 2022-12-31 | $112.98 Million | -22.76% |
| 2021-12-31 | $146.27 Million | -28.05% |
| 2020-12-31 | $203.29 Million | +6.37% |
| 2019-12-31 | $191.11 Million | +142.93% |
| 2018-12-31 | $78.67 Million | -- |
About Kymera Therapeutics Inc
Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing KT-621, an oral STAT6 degrader in Phase 2b clinical trials for moderate to severe atopic dermatitis, asthma, COPD, EoE, CR… Read more